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The most prevalent causative agent of urinary tract infections (UTIs) is uropathogenic
Escherichia coli, corresponding to 50–90% of uncomplicated, around 30–70% of
nosocomial UTIs. There has been renewed interest toward the clinical value of older,
nonb-lactam antibiotics (including fosfomycin, nitrofurantoin, trimethoprim/sulfameth-
oxazole) used for the therapy UTIs caused by drug resistant bacteria, including AmpC-
producing or an extended-spectrum b-lactamases (ESBL)-producing Gram-negative
strains. The aim of our study was to determine the resistance levels of AmpC-producing
or ESBL-producing E. coli strains, against the relevant ancillary antibiotics that may be
used in the treatment of UTIs. Isolates were collected from the time period between 1
January 2013 and 31 December 2017 from patients with uncomplicated and compli-
cated UTIs treated at the Albert Szent-Gy€orgyi Clinical Center (Szeged, Hungary).
Antibiotic susceptibility testing was carried out using the Kirby-Bauer method. Out of
the 10 837 isolates, n¼2010 (18.5%; 40243 isolates/year) E. coli isolates were either
AmpC-producers or ESBL-producers, whereas n¼1398 (12.8%; 28012 isolates/year)
produced the two groups of b-lactamases simultaneously. The highest levels of
coresistance overall was seen for ciprofloxacin (68.2%), followed by trimethoprim-
sulfamethoxazole (58.6%), whereas resistance levels were lower in regards to genta-
micin (39.0%), fosfomycin (20.3%) and considerably lower for nitrofurantoin (11.1%).
Our analysis of urine-specific AmpC-producing or ESBL-producing E. coli isolates is a
useful addition to the literature, as clinicians may rely on this data for empiric antibiotic
selection for UTI. Copyright  2020 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Urinary tract infections (UTIs) are one of the most
prevalent infections in human medicine, accounting for
10–20% of all infections in the community-setting and
25–50% of hospital-acquired infections [1,2]. The
economic losses due to UTIs (healthcare-related costs,
antibiotic-therapy, workplance absenteeism) are esti-
mated to be around 5 billion US$, as UTIs are responsible
for 10 million general practitioner (GP) visits, 1.5 million
emergency room visits and 300 000 hospital admissions in
the United States alone [3]. The common symptoms
associated with UTIs includeurinary urgency, dysuria,
suprapubic pain, feeling of incomplete bladder emptying
and visible blood in urine [4]. UTIs have been described
as an important infections in both sexes and in all age
groups (infants, children, adults and the elderly);
nonetheless, uncomplicated UTIs are most common
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between women over 18 years of age, with around two-
thirds of women in the ages of 20–40 years experiencing a
UTI at least once during their lifetime; in addition,
recurrent UTIs (rUTIs) in adult women is present in 20–
30% of cases, within 3–4 months of the initial infection
[5]. rUTIs are also frequently associated with psychiatric
symptoms, such as reduced social activity, guilt (due to
inability to perform various everyday tasks), anxiety (e.g.
associated with incontinence in the elderly) and
depression, which also major contributing factors to
the decreased quality of life associated with these
infections [6,7].
The most common causes of UTIs are the members of the
Enterobacterales order; these bacteria are abundantly
present in the gut microbiota within the anatomical
vicinity of the genito-urinary tract [1,2]. The most
prevalent uropathogen is the uropathogenic Escherichia
coli, corresponding to 50–90% of uncomplicated,
community-associated UTIs and around 30–70% of
nosocomial UTIs [8]. In addition to E. coli, other Gram-
negative bacteria, such as Klebsiella spp., members of the
CES (Citrobacter-Enterobacter-Serratia) group and the PPS
(Proteus-Providencia-Morganella) group, whereas among
Gram-positive bacteria, Enterococcus spp. and Staphylococ-
cus saprophyticus are also relevant uropathogens, especially
in older patients with an inserted urinary catheter [9–11].
The therapy of UTIs is mainly empirical, based on the
signs or symptoms of infections. The therapy of UTIs is an
increasingly complex challenge for GPs and urologists;
recent reports have shown a marked increase in the
resistance levels and the number of multidrug resistant
(MDR) isolates causing UTIs. MDR in E. coli has also
been shown, due to the excessive, imprudent use of
antibiotics [12]. E. coli has also been included in the group
of so-called ESKAPE bacteria, representing bacterial
pathogens, in which the developments of resistance were
the most concerning [13].
The recommended drugs for the treatment of uncom-
plicated UTIs include nitrofurantoin, fosfomycin, tri-
methoprim/sulfamethoxazole and mecillinam (if local
resistance levels do not exceed 20% per pathogen); if drug
hypersenstivity needs to be considered, then other
therapeutic options, such as b-lactam antibiotics,
fluoroquinolones and aminoglycosides should be primar-
ily used [14,15]. b-lactam-antibiotics (namely penicillins,
cephalosporins and carbapenems) are considered the
backbone of the therapy of bacterial infections, due to
their broad spectrum and advantageous pharmacokinetic
properties [16]. In addition, in several vulnerable patient
populations (children, pregnant women, patients with
liver/kidney failure), there drugs are the first-choice
agents, due to the teratogenicity or debilitating side
effect-profile of the alternate drugs [17]. Resistance to b-
lactam is mainly due to the presence of degrading
enzymes called b-lactamases: from a clinical standpoint of
UTIs, AmpC-type b-lactamases and extended-spectrum
b-lactamases (ESBLs) are the most prevalent, resulting in
therapeutic failures [16,17]. AmpC-type b-lactamases are
mostly chromosomally encoded, capable of hydrolyzing
penicillin-derivatives and cephalosporins (including third
generation cephalosporins and aztreonam, but not fourth
generation cephalosporins), whereas ESBLs are plasmid-
encoded enzymes, capable of hydrolyzing penicillin-
derivatives and cephalosporins (including third and fourth
generation cephalosporins) [18,19]. In UTIs with an
AmpC-producing or an ESBL-producing E. coli isolate,
carbapenems essentially remain the only safe drug choice,
whereas other ‘last resort’ agents (e.g. tigecycline, colistin,
ceftazidime-avibactam) are rarely used, due to their price,
pharmacokinetic profile or side effects. In addition,
isolates with plasmid-borne ESBLs most frequently carry
resistance determinants to other antibiotic classes as well
[18,19].
There has been renewed interest towards the clinical value
of older, nonb-lactam antibiotics (including fosfomycin,
nitrofurantoin, trimethoprim/sulfamethoxazole) used for
the therapy UTIs caused by drug resistant bacteria,
including AmpC-producing or an ESBL-producing
Gram-negative strains [20]. In fact the effectiveness of
fosfomycin was evaluated in vitro and in a clinical setting,
both for oral and parenteral administration [21].
Clinicians are encouraged to use these UTI-specific
antibiotics to treat their patients to spare b-lactams,
however, reliable susceptibility data is needed to ascertain
the safety and adequacy of the drug choices [22]. The
increase in the prevance of drug resistance in UTI-
causing pathogens has been reported in Hungary,
however, susceptibility-data for some antibiotics is scarce.
Therefore, the aim of our study was to determine the
resistance levels of AmpC-producing or ESBL-producing
E. coli strains isolated from UTIs, against the relevant
ancillary antibiotics that may be used in the treatment of
these infections, with a special focus on the Southern
Region of Hungary.
Materials and methods
Study design
The current study was carried out by collecting AmpC
and/or ESBL-positive E. coli isolates from the time period
between 1 January 2013 and 31 December 2017 from
patients with uncomplicated and complicated UTIs
treated at the Albert Szent-Gy€orgyi Clinical Center, a
1800-bed tertiary-care medical center, which annually
serves more than 400 000 patients in Szeged, Hungary [9].
Samples with clinically significant colony counts for the
abovementioned bacteria [105< colony forming units
(CFU)/ml]; however, this was subject to interpretation,
based on the information provided on the request forms
for microbiological analysis and relevant international
guidelines were included in the study. Only the first
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isolate per patient was included in the study, however,
isolates with different antibiotic-susceptibility patterns
were considered as different individual isolates. In
addition, limited patient data (age and sex of the affected
patients) was also collected, during the electronic search
in the records of the laboratory information system for
urine samples containing AmpC and/or ESBL-positive
E. coli.
Sample size determination
The sample size of AmpC and/or ESBL-positive E. coli
isolates required for the study from each year of the study
was determined using the formula by the methodology
described by Thrusfield (1), where n was the calculated
sample size, z the desired level of confidence (1.96), i the
standard sampling error (5%), and p the estimated
prevalence set at 30% [23,24]. The minimum required
sample size required (n¼ 249) was increased by 20% for
added contingency, thus the required sample size of 300/
year was determined.
n ¼ z
2 p 1 pð Þ
i2
(1)
Identification of isolates
An amount of 10ml each uncentrifuged urine sample was
cultured on UriSelect chromogenic agar plates (Bio-Rad,
Berkeley, California, USA) with a calibrated loop,
according to the manufacturer’s instructions. The plates
were incubated at 37 8C for 24–48 h, aerobically. If E. coli
was detected in significant colony counts, the plates were
passed on for further processing. Bacterial identification
was carried out using matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-
TOF MS). The methodology of sample preparation for
MALDI-TOF MS measurements was described previ-
ously [25]. Mass spectrometry measurements were
performed by the Microflex LT MALDI Biotyper
(Bruker Daltonics, Bremen, Germany) in positive linear
mode across the m/z range of 2–20 kDa; for each
spectrum, 240 laser shots at 60 Hz in groups of 40 shots
per sampling area were collected. The MALDI Biotyper
RTC 3.1 software (Bruker Daltonics) and the MALDI
Biotyper Library 3.1 were used for spectrum analysis.
Antimicrobial susceptibility testing, resistotyping
Susceptibility testing was performed for antibiotics
relevant in the treatment of UTIs caused by AmpC
and/or ESBL-positive E. coli, using the Kirby–Bauer disk
diffusion method (Liofilchem, Abruzzo, Italy) on
Mueller–Hinton agar plates. Verification of discrepant
results was performed using the VITEK 2 Compact ID/
AST (bioMerieux, Marcy-l’Etoile, France) automated
system. The following antibiotics were included in the
study: ertapenem (10mg), ciprofloxacin (5mg), gentami-
cin (10mg), fosfomycin (200mg), nitrofurantoin (100mg)
and trimethoprim-sulfamethoxazole (23.75/1.25mg).
The interpretation of the results was based on the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) breakpoints, available at the time of
isolation. During data analysis, intermediately-susceptible
results were grouped with and reported as resistant.
Classification of isolates as MDR and extensively drug
resistant (XDR) was based on the criteria of Magiorakos
et al. [26]. Resistotypes from the respective susceptibility-
results were defined based on criteria described
previously [27]. Staphylococcus aureus ATCC 29213,
Enterococcus faecalis ATCC 29212, Proteus mirabilis ATCC
35659, E. coli ATCC 25922, K. pneumoniae ATCC
700603 and Pseudomonas aeruginosa ATCC 27853 were
used as quality control strains.
Detection of AmpC and extended-spectrum b-
lactamases-production
Screening for b-lactamase production was performed on
the basis of the recommendations of EUCAST. For the
purposes of this study, AmpC and ESBL-producing
strains were not further differentiated and their molecular
characterization was not performed.
Screening of E. coli isolates for AmpC b-lactamase
production was carried out using cefoxitin disks (10mg):
isolates with a zone of inhibition of 18 mm or less was
considered as a potential AmpC-producer [16]. ESBL-
production was suspected, if the isolates showed resistance
toward third-generation cephalosporins (either cefotax-
ime, ceftriaxone, ceftazidime) during routine suscepti-
bility testing. ESBL-detection was carried out using the
AmpC-ESBL Detection Set (MAST Diagnostica GmbH,
Reinfeld, Germany) and VITEK 2 Compact ID/AST
(bioMerieux), according to the manufacturer’s instruc-
tions [10].
Statistical analysis
Descriptive statistical analysis (including means or
medians with ranges and percentages to characterize
data) was performed using Microsoft Excel 2013
(Microsoft Corp., Redmond, Washington, USA).
Ethical considerations
The study was deemed exempt from ethics review by the
Institutional Review Board, and informed consent was
not required as data anonymity was maintained.
Results
Demographic characteristics, isolation
frequency
During the 5-year study period (1 January 2013–31
December 2017), the Institute of Clinical Microbiology
received 19 387 urine samples (originating from inpatient
departments and outpatient clinics, respectively) that
turned out to be positive for a significant urinary
pathogen. Out of the positive urine samples E. coli
Revival of older antibiotics GajdacsAQ1 et al. 3
CE: Swati; RMM-D-20-00036; Total nos of Pages: 7;
RMM-D-20-00036
represented the majority (55.9 6.5%; n¼ 10 837) of
relevant urinary isolates.
The median age of affected patients by E. coli UTIs
overall, was 61 years (range: 0.3–96), with a female-to-
male ratio of 3.02, whereas for the patients affected by
AmpC-producers or ESBL-producers, this was 74 years
(range: 24–97), with a female-to-male ratio of
2.21, respectively.
Resistance levels of AmpC-producing and
extended-spectrum b-lactamases-producing
Escherichia coli
Out of the 10 837 isolates, n¼ 2010 (18.5%; 402 43 iso-
isolates/year) E. coli isolates were either AmpC-producers
or ESBL-producers (thus, fulfilling our requirements for
minimum sample size), whereas n¼ 1398 (12.8%;
280 12 isolates/year) produced the two groups of b-
lactamases simultaneously. The complete epidemiology
and resistance levels of the relevant isolates is presented in
Table 1. Among AmpC-producing or ESBL-producing
E. coli isolates, the highest levels of coresistance overall was
seen for ciprofloxacin (68.2%), followed by trimetho-
prim-sulfamethoxazole (58.6%), whereas resistance levels
were lower in regards to gentamicin (39.0%), fosfomycin
(20.3%) and considerably lower for nitrofurantoin
(11.1%). Lowest levels of resistance were seen for
ertapenem (only 3 isolates), which was not surprising,
as the prevalence of carbapenem-resistant isolates is low in
this geographical region.
The distribution of isolates into various resistotypes is
shown in Table 2.; Type 0 represents E. coli isolates
AmpC-producers or ESBL-producers, but are otherwise
fully-susceptible to the ancillary urinary antibiotics tested
(31.7%), Type I (I-A, I-B and I-C) includes isolates
resistant to either ciprofloxacin, trimethoprim-sulfa-
methoxazole or gentamicin only (24.6%); whereas Type
II (II-A, II-B, II-C and II-D) introduces resistance to
multiple antibiotics at once, and resistance to nitrofur-
antoin and fosfosmycin, respectively (41.1%). Type III
(2.5%) represents resistance to five, whereas Type IV
(0.1%) represents resistance to all individual antibiotics
tested. Based on EUCAST Expert Rules, isolates in the
Type III category also represent MDR E. coli isolates,
whereas isolates in the Type IV category should be
considered as XDR isolates.
Discussion
The diagnosis and treatment of UTIs are a considerable
burden on healthcare systems [1–3]. E. coli and other
members of the Enterobacterales order are shown to be
successful pathogens in the urinary system, as they possess
the relevant virulence factors required to successfully
survive on and adhere to urinary epithelium. In addition,
after successful adherence, they may also cause damage to
the tissues, ascent to the upper urinary tract and cause
cUTIs [1–3,8]. The following virulence-determinants
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Table 1. Isolation frequency and resistance levels associated with AmpC-producing or extended-spectrum b-lactamases-producing Escherichia
coli from urinary tract infections (2013–2017).
AmpC-producing or
ESBL-producing isolates
AmpC-producing and
ESBL-coproducing isolates Ertapenem Ciprofloxacin Gentamicin Fosfomycin Nitrofurantoin
Trimethoprim-
sulfarmethoxazole
2013 364 261 (71.7%) 0 (0.0%) 276 (75.8%) 167 (45.8%) 66 (18.1%) 36 (9.9%) 215 (59.2%)
2014 389 284 (73.0%) 0 (0.0%) 333 (85.7%) 130 (33.3%) 75 (19.2%) 46 (11.8%) 222 (57.1%)
2015 476 287 (60.3%) 1 (0.1%) 279 (58.5%) 182 (38.2%) 114 (23.9%) 56 (12.4%) 268 (56.2%)
2016 394 291 (73.8%) 1 (0.1%) 289 (73.4%) 150 (38.1%) 66 (16.7%) 45 (11.4%) 227 (57.8%)
2017 387 275 (71.0%) 1 (0.1%) 195 (70.9%) 155 (40.0%) 87 (22.1%) 40 (10.3%) 245 (63.2%)
Overall 2010 1398 (69.6%) 3 (0.1%) 1372 (68.2%) 784 (39.0%) 408 (20.3%) 223 (11.1%) 1177 (58.6%)
ESBL, extended-spectrum b-lactamases.
Table 2. Distribution of various resistotypes among AmpC-producing or extended-spectrum b-lactamases-producing Escherichia coli from
urinary tract infections (2013–2017).
Resistotype Ciprofloxacin
Trimethoprim-
sulfamethoxazole Gentamicin Fosfomycin Nitrofurantoin Ertapenem
Number of
isolates
0 S S S S S S 638 (31.7%)
I-A R AQ9S S S S S 333 (14.3%)
I-B S R S S S S 138 (5.7%)
I-C S S R S S S 112 (4.6%)
II-A R R S S S S 147 (6.3%)
II-B R R R S S S 264 (11.1%)
II-C R R S R S S 405 (16.5%)
II-D R R S S R S 160 (7.2%)
III R R R R R S 60 (2.5%)
IV R R R R R R 3 (0.1%)
ESBL, extended-spectrum b-lactamases; R, resistant; S, susceptible.
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were determined having principal roles in the pathogen-
esis of UTIs: lipopolysaccharide, polysaccharide capsule,
outer membrane vesicles, iron-uptake (aerobactin) and
siderophore receptors, adhesins, Type-1 fimbriae, cyto-
toxins and urease production [8,10,28]. These virulence
factors are also relevant in their survival on abiotic
surfaces, like in hospital wards, catheters [2,8,10,28].
Ideally, the effective therapy of bacterial UTIs relies on
identification of the causative organism and the selection
of an effective antibiotic agent, which is made possible by
continuous surveillance of antimicrobial susceptibility
patterns of uropathogens in the well defined geographical
region [29]. The emergence of b-lactam-resistance
depending on the presence of AmpC-based and ESBL-
based enzymes in UTIs is a serious public health issue,
which is only expected to worsen, due to the slow but
growing incidence of carbapenemase-producing strains
[30,31]. The overuse of b-lactams in inappropriate
indications, or as self-medication with antibiotics,
enhances the selection pressure put onto these micro-
organisms [32,33]. Since the beginning of the 21st
century, blaCTX-M-type ESBLs are the most prevalent
around the globe, with pronounced genetic diversity
among the various subtype of these enzymes; among
AmpC-enzymes, blaCMY and blaDHA types are the most
prevalent [18,30,34]. Due to their transmissibility, ESBLs
are considered a serious public health/infection control
issue, especially because these enzymes are encoded on
larger-sized plasmids [18,30,34]. As several resistance-
determinants are often present in bacteria simultaneously,
in addition to b-lactams, other antibiotic-groups may be
affected, rapidly resulting in MDR, or even XDR strains,
with severely limited therapeutic options left [26,35].
These isolates have been associated with increased
morbidity and mortality, particularly in ICUs and in
severely immunocompromised patients [36].
Our analysis of urine-specific AmpC-producing or
ESBL-producing E. coli isolates is a useful addition to
the literature, as clinicians may rely on this data for
empiric antibiotic selection for UTI. Our study has
highlighted that E. coli is the most frequently occurring
pathogen in UTIs in our tertiary-care teaching hospital,
and that almost one in every fifth isolated E. coli expressed
either AmpC-type or ESBL-type b-lactamases, or both of
them. In addition, our report has shown that more, than
40% of these isolates were resistant to at least two nonb-
lactam antibiotics, relevant in the therapy of UTIs.
Resistance to the preferred UTI-antibiotics was variable;
whereas resistance levels to nitrofurantoin slightly went
above 10%, fosfomycin was above 20% and resistance to
trimethoprim/sulfamethoxazole was almost 60%. Thus,
among these agents, the empiric use of nitrofurantoin
may be considered well treated, even in the case of isolates
carrying AmpC-type or ESBL-type b-lactamases,
whereas for fosfomycin and trimethoprim/sulfamethox-
azole, susceptibility-testing is recommended (according
to the guidelines of the Infectious Diseases Society of
America) [1,2]. Fosfomycin-resistance was shown to be
around 3–50% in Enterobacterales in various literature
sources, however, the resistance levels are usually lowest in
E. coli, and steadily increasing in CES pathogens and
Klebsiella spp. [9–12,21,37]. Fosfomycin and nitrofur-
antoin both have unique chemical structures and
mechanisms of action, therefore, these is no need to
expect cross-resistance with other antibacterial drugs [9–
12,21,38]. The utility of trimethoprim/sulfamethoxazole
in the therapy of ESBL-positive and carbapenemase-
positive Gram-negative isolates has been reported
previously, both in UTIs and invasive infections [39];
nevertheless, this was not highlighted in our study.
In conclusion, the aim of our study was produce reliable
data on the utility of various older or ancillary antibiotics
for the treatment of UTIs with a special focus on the
Southern Region of Hungary, if the causative agent has
been identified as a AmpC-producing or ESBL-produc-
ing E. coli isolate. As UTIs are among the most common
reasons for seeking medical attention in the community
and the introduction of antibiotics in nosocomial settings,
knowledge of resistance-trends is of utmost importance,
as the emergence of MDR strains of uropathogens, results
in therapeutic difficultures and clinical failure [40].
Some limitations of this study must be acknowledged:
first, the study was carried out for E. coli only, and this is
not representative for all urine isolates belonging to the
Enterobacterales order; second, data was not collected on
the inpatient/outpatient status and the presence of a
urinary catheter in affected patients; third, molecular
characterization of the genetic background of resistance
in the individual isolates was not performed; fourth,
selection bias must be taken into consideration.
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